2022-RA-934-ESGO Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity sub-study

Abstract

2022-RA-934-ESGO Figure 1 Vaginal changes clinical measuremnts over time (some of the CTCAE and additional assessments). The proportion of woman is shown in percentages. BM = baseline measurement; CTCAE = common terminology criteria for adverse events; DM = diameter; M = months; N = number of woman astrisk at the specific timepoint; O = observed number of women at the specific timepoint; W = weeks Results 113 eligible patients were included. Over time, mild (grade 1) vaginal changes were reported in 10.8–36.8% of the participants. Of the 113 participants, 46.7% reported not being sexually active at 24 months, mostly because of losing interest in sex or lacking a partner. Among the sexually active women (41–54/113), 43.2–51.3% reported vaginal functioning problems starting at 4–6 weeks and more severe sexual problems and distress were reported by 5–15% of them. Significant differences (p£.05) in physician-assessed vaginal morbidity were found between baseline and follow-up, without further clear changes. No or only small associations between vaginal changes and vaginal functioning problems and sexual distress were found. Conclusion Relatively mild vaginal changes were reported after image-guided radio(chemo)therapy and brachytherapy according to EMBRACE-protocol. Vaginal functioning problems were reported by almost half of the sexually active women, while more severe problems and distress were reported by up to 15% of them. These results are favourable compared to previous data, potentially due to the combination of tumours with limited vaginal involvement and EMBRACE-specific treatment optimization and rehabilitation recommendations. 2022-RA-958-ESGO INVASIVE STRATIFIED MUCIN-PRODUCING INTRAEPITHELIAL LESION (ISMILE) A RARE ENTITY OF CERVICAL CANCER Zeineb Zemni, Mohamed Rebei, Sarah Amari, Manel Abbes, Outeyba Belkhayatia, Anis Fadhlaoui, Moez Kdous, Monia Ferchiou. Aziza othmana hospital, tunis, Tunisia 10.1136/ijgc-2022-ESGO.75 Introduction/Background ISMILE adenocarcinoma is a rare entity, recently described as a distinct entity of invasive lesion associated with Human Papilloma Virus infection. Described in the few cases in the literature as a form with a poor prognosis. Clinical and prognostic data of this entity are very limited in the literature. In this case, we describe the clinical presentation, management and two-year follow-up of an invasive SMILE adenocarcinoma. Methodology A 47-year-old female patient, with no pathological history, mother of 3 children, not yet menopausal, who had no previous cervical cancer screening; the reason for consultation was vaginal bleeding and pelvic pain. Examination found a suspicious 4 cm budding and exophytic cervical mass. Abstract 2022-RA-958-ESGO Figure 12022-RA-958-ESGO Figure 1 Results The appearance was in favour of a SMILE adenocarcinoma in situ with early cervical invasion. The tumour was classified as FIGO stage IIB. Treatment consisted of chemotherapy, external pelvic radiotherapy and neoadjuvant uterovaginal brachytherapy. Operated within one month she had a total hysterectomy associated with an inguinal lymphadenectomy. Final pathological examination concluded to a localized invasive cervical tumor type SMILE measuring 4 cm. Followup was without recurrence after 2 years. Abstract 2022-RA-958-ESGO Figure 2 Abstracts2022-RA-958-ESGO Figure 2 Abstracts Int J Gynecol Cancer 2022;32(Suppl 2):A1–A504 A35 on D ecem er 4, 2022 by gest. P rocted by coright. http/ijgc.bm jcom / nt J G ynecol C acer: frst pulished as 10.11ijgc-2022-E S G O 74 on 20 O cber 222. D ow nladed fom